{"id":428,"date":"2020-08-06T10:46:33","date_gmt":"2020-08-06T10:46:33","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=428"},"modified":"2020-08-06T10:46:33","modified_gmt":"2020-08-06T10:46:33","slug":"05-aug-2020-favipiravir-demonstrated-rapid-antiviral-response-against-sars-cov-2","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/05-aug-2020-favipiravir-demonstrated-rapid-antiviral-response-against-sars-cov-2\/","title":{"rendered":"(05 Aug 2020) Favipiravir- demonstrated rapid antiviral response against SARS-CoV-2"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>AVIFAVIR for Treatment of Patients with Moderate COVID-19:<br \/>\nInterim Results of a Phase II\/III Multicenter Randomized Clinical Trial<\/p>\n<p>https:\/\/doi.org\/10.1101\/2020.07.26.20154724<\/p>\n<p class=\"\">In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II\/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II\/III Multicenter Randomized Clinical Trial https:\/\/doi.org\/10.1101\/2020.07.26.20154724 In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/05-aug-2020-favipiravir-demonstrated-rapid-antiviral-response-against-sars-cov-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(05 Aug 2020) Favipiravir- demonstrated rapid antiviral response against SARS-CoV-2&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,11],"tags":[26],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/428"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=428"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/428\/revisions"}],"predecessor-version":[{"id":429,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/428\/revisions\/429"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}